Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2022 | Percentile | Sector n |
|---|---|---|---|---|
| Tsiurikhis Sameditsino … | Healthcare Services | 10.4% | 47th pct | 296 |
| Sena-Medi | Healthcare Services | 2.9% | 27th pct | 296 |
| LJ Da Company - Dasavle… | Healthcare Services | -0.5% | 19th pct | 296 |
| Mardaleishvili Medical … | Healthcare Services | -48.7% | 3rd pct | 296 |
| Academician N. Kipshidz… | Healthcare Services | -73.0% | 3rd pct | 296 |
Percentile is within each company's own sector across the whole FY2022 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2022 | Academician N. Kipshidz… | LJ Da Company - Dasavle… | Sena-Medi | Mardaleishvili Medical … | Tsiurikhis Sameditsino … |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 43.8% | 12.0% | 68.7% | 100.0% | 44.2% |
| EBITDA Margin | -73.0% | -0.5% | 2.9% | -48.7% | 10.4% |
| EBITDAR | -18,600 | -31 | 182 | -1,869 | 421 |
| EBITDAR Margin | -73.0% | -0.5% | 3.3% | -48.7% | 12.5% |
| EBIT Margin | -90.5% | -6.5% | -2.7% | -48.7% | 8.5% |
| Net Profit Margin | -1.9% | 0.2% | -6.2% | -23.8% | 10.4% |
| Operating Expense % of Sales | 116.7% | 12.5% | 65.8% | 148.7% | 33.8% |
| Returns | |||||
| Return on Assets (ROA) | -0.6% | 0.2% | -6.5% | -7.9% | 48.1% |
| Return on Equity (ROE) | -1.3% | 1.3% | -17.1% | N/A | 70.1% |
| ROIC [EBIT / Invested Capital] | |||||
| -174.3% |
| -66.0% |
| -5.8% |
| -18.3% |
| 58.8% |
| Leverage & debt balances | |||||
| Debt-to-Assets | 2.5% | 0.7% | 17.4% | 90.3% | 0.8% |
| Debt-to-Equity | 0.05x | 0.06x | 0.46x | -62.92x | 0.01x |
| Debt-to-EBITDA | N/A | N/A | 5.78x | N/A | 0.02x |
| Equity-to-Assets | 46.3% | 12.6% | 38.0% | -1.4% | 68.6% |
| Net Debt | -24,147 | -231 | 591 | 10,389 | -8 |
| Cash & Equivalents | 26,160 | 278 | 322 | 91 | 13 |
| Total Debt | 2,013 | 46 | 912 | 10,480 | 6 |
| Liquidity & working capital | |||||
| Current Ratio | 2.28x | 0.49x | 0.86x | 0.00x | 1.48x |
| Quick Ratio | 1.66x | 0.49x | 0.86x | -0.57x | 1.48x |
| Cash Ratio | 1.38x | 0.05x | 0.18x | 0.07x | 0.06x |
| Total Current Assets | 43,159 | 2,820 | 1,521 | 0 | 338 |
| Total Current Liabilities | 18,949 | 5,714 | 1,764 | 1,254 | 228 |
| Inventory | 11,779 | N/A | N/A | 720 | N/A |
| Trade Receivables | 5,220 | 1,253 | 1,521 | 1,167 | 181 |
| Trade Payables | 12,745 | 562 | 1,764 | 1,021 | 222 |
| Net Working Capital | 24,210 | -2,894 | -243 | -1,254 | 110 |
| Net Working Capital % of Revenue | 95.0% | -48.0% | -4.4% | -32.7% | 3.2% |
| Trade Working Capital | 4,254 | 691 | -243 | 865 | -41 |
| Trade Working Capital % of Revenue | 16.7% | 11.5% | -4.4% | 22.5% | -1.2% |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | N/A |
| Turnover & efficiency | |||||
| Inventory Turnover | 1.22x | N/A | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | 299.9 | N/A | N/A | N/A | N/A |
| Receivables Turnover | 4.88x | 4.81x | 3.60x | 3.29x | 18.63x |
| Days Sales Outstanding (DSO) | 74.7 | 75.8 | 101.4 | 110.9 | 19.6 |
| Payables Turnover | 1.12x | 9.44x | 0.97x | N/A | 8.48x |
| Days Payable Outstanding (DPO) | 324.4 | 38.7 | 375.6 | N/A | 43.0 |
| Cash Conversion Cycle | 50.1 days | 37.2 days | -274.2 days | 110.9 days | -23.4 days |
| Asset Turnover | 0.32x | 0.92x | 1.05x | 0.33x | 4.64x |
| Cash flow & dividends | |||||
| Operating Cash Flow | -6,844 | -537 | -277 | -1,379 | 145 |
| Free Cash Flow (OCF − Capex proxy) | -5,330 | -537 | -277 | -1,379 | 38 |
| Cash Conversion (OCF / EBITDA) | N/A | N/A | -175.5% | N/A | 41.3% |
| Dividends Declared | 0 | N/A | N/A | 0 | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A |